Immunotherapy with depigmented glutaraldehyde-polymerized extracts: changes in quality of life

Authors

  • E. Álvarez-Cuesta,

  • E. Aragoneses-Gilsanz,

  • C. Martín-García,

  • P. Berges-Gimeno,

  • E. González-Mancebo,

  • J. Cuesta-Herranz


In [1], on page 574, the text of the second paragraph has a mistake (in bold): “Two vials were prepared to be used as a therapeutic vaccine. Vial no. 2 contained 270 μg of D. glomerata and 280 μg of O. europaea, which were the result of depigmenting and polymerizing 100 HEPL, corresponding to 750 μg of freeze-dried extract of D. glomerata (60 μg/mL Dac g 2, 20 μg/mL Dac g 1+5) and 3550 μg of freeze-dried extract of O. europaea (131 μg/mL Ole e 1). Vial no. 1 was a 10-fold dilution of vial no. 2.”

The correct text is “Two vials were prepared to be used as a therapeutic vaccine. Vial no. 2 contained 270 μg of D. glomerata and 280 μg of O. europaea, which were the result of depigmenting and polymerizing 1000 HEPL, corresponding to 750 μg of freeze-dried extract of D. glomerata (60 μg/mL Dac g 2, 20 μg/mL Dac g 1+5) and 3550 μg of freeze-dried extract of O. europaea (131 μg/mL Ole e 1). Vial no. 1 was a 10-fold dilution of vial no.2.”

Ancillary